INI1 negative sarcoma diagnosed as malignant rhabdoid tumor presenting as hydrops fetalis metastatic to the placenta: a case report and review of the literature on congenital sarcomas
We present a case of a 19-year-old woman with Ewing sarcoma of the iliac bone in whom 68Ga-PSMA-HBED-CC PET/CT showed high radiotracer activity in the primary tumor. The present case documents the in vivo expression of PSMA in Ewing sarcoma family of tumors and adds on to the list of nonprostatic malignancies showing PSMA expression.
No abstract available
CONCLUSIONS: SNHG14 contributed to cell proliferation, migration and invasion, while suppressed apoptosis in CRC cells by targeting miR-944/KRAS axis through PI3K/AKT pathway, representing novel biomarkers for CRC therapy. PMID: 31799655 [PubMed - in process]
We describe the clinical, pathological and genetic features in a 42 year old male with a 3 month history of arm weakness. MRI of the cervical spine with and without contrast revealed an intradural, extra-axial enhancing lesion involving the spinal canal from the foramen magnum to the level of C4. Partial surgical resection revealed a malignant neuroepithelial tumor. Genetic analysis identified a EWSRA-FLI1 (exon 7-exon 6) fusion, transcript suggesting classification as a Ewing's sarcoma/primitive neuroectodermal tumor. The case highlights the variability in the presentation of ES and value of genetic testing in a...
In conclusion, primary sarcomas of the larynx a re rare but tend to present with early symptoms. This likely allows for earlier detection and intervention as compared to their counterparts in other deep soft tissue locations. Pathologically, it is important, although difficult in some cases, to distinguish these neoplasms from sarcomatoid carcino ma and reactive processes. Careful morphologic and immunohistochemical evaluation, as well as correlation with the clinical and radiologic findings, is important for accurate tumor classification.
ConclusionPlerixafor proved effective to mobilize adequate numbers of PBSCs in individual patients with relapsed malignancies after prior single or tandem HDC+PBSCT. These PBSCs could establish sustained multi-lineage hematopoietic engraftment without any sequelae.
Condition: Retroperitoneal Sarcoma Interventions: Drug: Liposomal Bupivacaine; Drug: Quadratus Lumborum Block; Other: Questionnaire Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting
This report describes a woman aged 22 years with unresectable ALK-negative IMT. Next-generation sequencing revealed a TFG-ROS1 fusion, and she had a partial response to the ROS1 inhibitor ceritinib. This report provides the first published demonstration of a patient with IMT with ROS1 fusion successfully treated using ceritinib. Our study suggests that targeting ROS1 fusions using the small molecule inhibitor shows promise as an effective therapy in patients with IMT carrying this genetic alteration, but this requires further investigation in large clinical trials. PMID: 31805529 [PubMed - in process]
In conclusion, the anti-proliferative effects of SFN indicate its potential as a new substance for the treatment of PEL. PMID: 31787726 [PubMed - in process]
In conclusion, the histopathological presence of Homer-Wright rosettes and immunohistochemical markers such as CD99, FLI-1 and CK are valuable factors for the diagnosis of ES, although cytogenetic analysis is considered the gold standard. Complete surgery is the most effective treatment option for ES treatment. Adjuvant radiotherapy and combination chemotherapy can also improve the survival rate of patients postoperatively. PMID: 31788090 [PubMed]